检测胃癌患者血清中 TFPI2 的甲基化。

Detection of TFPI2 methylation in the serum of gastric cancer patients.

机构信息

Gastroenterological Surgery, Showa University Fujigaoka Hospital, 1-30 Fujigaoka, Aoba-ku, Yokohama 227-8501, Japan.

出版信息

Anticancer Res. 2011 Nov;31(11):3835-8.

Abstract

BACKGROUND

Methylation of tissue factor pathway inhibitor-2 (TFPI2) has been detected in the stool of colorectal cancer patients. Using quantitative methylation-specific polymerase chain reaction (qMSP), 39 out of 215 (18%) patients exhibited TFPI2 methylation in their serum DNA, suggesting that a significant number of methylated TFPI2 existed in colorectal cancer patients' sera.

MATERIALS AND METHODS

Methylation status of the TFPI2 gene was examined in sera derived from 73 patients with gastric cancer using qMSP and the correlation between the methylation status and the clinicopathological findings was evaluated.

RESULTS

Out of 73 serum samples, 7 (10%) exhibited TFPI2 methylation in their serum DNA by qMSP, suggesting that TFPI2 methylation existed in the serum of gastric cancer patients. After completion of qMSP analysis of all specimens, clinicopathological data were correlated with the molecular analysis. TFPI2 methylation was significantly more frequently found in serum of patients with lymph node metastasis (p=0.0040) and distant metastasis (p=0.0115).

CONCLUSION

In principle, knowledge of the methylation status of a primary tumor is not required in advance in order to be able to detect circulating tumor DNA. Therefore, qMSP could be used as a cancer screening method.

摘要

背景

组织因子途径抑制物-2（TFPI2）的甲基化已在结直肠癌患者的粪便中检测到。使用定量甲基化特异性聚合酶链反应（qMSP），215 名患者中有 39 名（18%）的血清 DNA 中存在 TFPI2 甲基化，这表明大量甲基化的 TFPI2 存在于结直肠癌患者的血清中。

材料和方法

使用 qMSP 检测 73 名胃癌患者血清中的 TFPI2 基因甲基化状态，并评估其与临床病理发现的相关性。

结果

在 73 份血清样本中，有 7 份（10%）通过 qMSP 在血清 DNA 中显示 TFPI2 甲基化，这表明 TFPI2 甲基化存在于胃癌患者的血清中。在对所有标本进行 qMSP 分析后，将临床病理数据与分子分析相关联。TFPI2 甲基化在有淋巴结转移的患者血清中（p=0.0040）和有远处转移的患者血清中（p=0.0115）更为常见。